Immatics (IMTX) Income towards Parent Company (2019 - 2025)
Immatics (IMTX) reported Income towards Parent Company of -$41.2 million for Q4 2025, down 186.03% on a YoY basis from $47.9 million in Q4 2024, and up 30.55% sequentially from -$59.4 million in Q3 2025.
Immatics (IMTX) Income towards Parent Company (2019 - 2025) Analysis & Trends
Immatics (IMTX) has 7 years of Income towards Parent Company data on file, last reported at -$41.2 million in Q4 2025.
- For the quarter ending Q4 2025, Income towards Parent Company fell 186.03% year-over-year to -$41.2 million; the trailing twelve-month figure through Dec 2025 stood at -$226.5 million (down 1530.58% YoY), and the FY2025 full-year result was -$221.9 million, down 1447.51% from the prior year.
- Income towards Parent Company improved to -$41.2 million in Q4 2025, from -$59.4 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $96.1 million in Q1 2022 to a low of -$81.9 million in Q2 2025.
- A 5-year average of -$17.0 million and a median of -$23.4 million in 2022 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company jumped 449.38% in 2022 and plunged 1188763.81% in 2024, its largest moves.
- Tracing IMTX's Income towards Parent Company over 5 years: stood at -$19.2 million in 2021, then surged by 111.78% to $2.3 million in 2022, then plunged by 1343.81% to -$28.1 million in 2023, then soared by 270.4% to $47.9 million in 2024, then slumped by 186.03% to -$41.2 million in 2025.
- Business Quant data shows IMTX's Income towards Parent Company at -$41.2 million in Q4 2025, -$59.4 million in Q3 2025, and -$81.9 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Immatics | 1.11 Bn | 1.11 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -41.24 Mn |
| Sep 30, 2025 | -59.39 Mn |
| Jun 30, 2025 | -81.90 Mn |
| Mar 31, 2025 | -44.01 Mn |
| Dec 31, 2024 | 47.94 Mn |
| Sep 30, 2024 | -9.41 Mn |
| Jun 30, 2024 | -19.38 Mn |
| Mar 31, 2024 | -3.32 Mn |
| Dec 31, 2023 | -28.13 Mn |
| Sep 30, 2023 | -28.84 Mn |
| Jun 30, 2023 | -26.80 Mn |
| Mar 31, 2023 | -279.07 |
| Dec 31, 2022 | 2.26 Mn |
| Sep 30, 2022 | -19.98 Mn |
| Jun 30, 2022 | -12.47 Mn |
| Mar 31, 2022 | 96.14 Mn |
| Dec 31, 2021 | -19.20 Mn |
| Sep 30, 2021 | -32.08 Mn |
| Jun 30, 2021 | -31.95 Mn |
| Mar 31, 2021 | -27.52 Mn |